August 5, 2021
“NexPoint Real Estate Finance (NREF)… There are only two recent reviews on record for NREF shares, but they both agree – this is a stock to buy. Their agreement gives the shares their Moderate Buy consensus rating. NREF is trading for… Continue Reading…
February 24, 2021
“Annaly Capital Management (NLY)… Overall, there is broad agreement on Wall Street about NLY’s quality, as shown by the 7 to 1 split among the analyst reviews, favoring Buy over Hold and giving the stock a Strong Buy analyst consensus… Continue Reading…
February 10, 2021
“When you sell a capital asset for more than you paid for it, the result is a capital gain. Capital assets include stocks, bonds, precious metals, jewelry, and real estate.1 The tax you’ll pay on the capital gain depends on… Continue Reading…
January 20, 2021
“Ready Capital Corporation (RC)… There are two recent reviews of Ready Capital and both are Buys, giving the stock a Moderate Buy consensus rating. Shares in this REIT are selling for $11.57 while the average price target stands at $13.63, indicating… Continue Reading…
December 18, 2020
“TC Pipelines LP (TCP)… The analyst consensus on TCP is not unanimous, but almost. The Strong Buy consensus rating is supported by 3 Buys against a single Hold. Shares sell for $30.39, and the average price target of $40.33 indicates an… Continue Reading…
December 10, 2020
“Ellington Financial (EFC)… In line with his comments, Hagen sets a Buy rating and a price target of $16.50, suggesting an upside of 10% for the coming year… Overall, Wall Street agrees that this stock is a buying proposition. The… Continue Reading…
December 2, 2020
“Cellectar Biosciences (CLRB)… Are other analysts in agreement? They are. 5 Buys and no Holds or Sells have been issued in the last three months. So, the message is clear: CLRB is a Strong Buy. Given the $5.48 average price… Continue Reading…
October 30, 2020
“Altria Group, Inc. (MO)… Overall, Altria has a Moderate Buy rating from the analyst consensus, based on 3 Buys and 2 Holds set in recent weeks. The stock’s current share price is $37.04, and the average price target of $46 suggests… Continue Reading…
September 30, 2020
“Seelos Therapeutics (SEEL)… Turning now to the rest of the Street, 2 Buys and no Holds or Sells have been published in the last three months. Therefore, SEEL has a Moderate Buy consensus rating. With the average price target clocking… Continue Reading…
Recent Comments